Retrospective study of S-1 versus tegafur/uracil and oral leucovorin in patients with metastatic colorectal cancer

Kotaro Shibahara; Manabu Yamamoto; Yoshihiro Kakeji; Hisanobu Sakata; Yoshihiko Maehara

Retrospective study of S-1 versus tegafur/uracil and oral leucovorin in patients with metastatic colorectal cancer

Kotaro Shibahara, Manabu Yamamoto, Yoshihiro Kakeji, Hisanobu Sakata, Yoshihiko Maehara

Surgery

Research output: Contribution to journal › Article › peer-review

Abstract

The aim of this study was to compare the efficacy and toxicity of S-l to an oral combination regimen of tegafur and uracil (UFT) with leucovorin (LV) in metastatic colorectal carcinoma (CRC) patients. Patients and Methods: Fifty-two patients were treated with either S-l (80 mg/m²/d), administered for 28 days every 42 days, or UFT (300 mg/m²/d) and LV (90 mg/d), administered for 28 days every 35 days. The clinical results were compared retrospectively. Results: There were no statistically significant differences in overall response between the two patient groups. The overall response rate was 11.8% in the S-l group, and 11.1% in the UFT/LV group. No statistically significant difference in-time- to progression (TTP) or survival time was observed between the treatments. The median survival time was 29 months with S-l and 12 months with UFT/LV. Conclusion: The oral S-l provided similar safety and efficacy, compared to UFT/LV for metastatic CRC.

Original language	English
Pages (from-to)	1779-1784
Number of pages	6
Journal	Anticancer research
Volume	28
Issue number	3 B
Publication status	Published - May 2008

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{73a97ad6de8a4f8caa9f8f64e5f98dbb,

title = "Retrospective study of S-1 versus tegafur/uracil and oral leucovorin in patients with metastatic colorectal cancer",

abstract = "The aim of this study was to compare the efficacy and toxicity of S-l to an oral combination regimen of tegafur and uracil (UFT) with leucovorin (LV) in metastatic colorectal carcinoma (CRC) patients. Patients and Methods: Fifty-two patients were treated with either S-l (80 mg/m2/d), administered for 28 days every 42 days, or UFT (300 mg/m2/d) and LV (90 mg/d), administered for 28 days every 35 days. The clinical results were compared retrospectively. Results: There were no statistically significant differences in overall response between the two patient groups. The overall response rate was 11.8% in the S-l group, and 11.1% in the UFT/LV group. No statistically significant difference in-time- to progression (TTP) or survival time was observed between the treatments. The median survival time was 29 months with S-l and 12 months with UFT/LV. Conclusion: The oral S-l provided similar safety and efficacy, compared to UFT/LV for metastatic CRC.",

author = "Kotaro Shibahara and Manabu Yamamoto and Yoshihiro Kakeji and Hisanobu Sakata and Yoshihiko Maehara",

year = "2008",

month = may,

language = "English",

volume = "28",

pages = "1779--1784",

journal = "Anticancer research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "3 B",

}

TY - JOUR

T1 - Retrospective study of S-1 versus tegafur/uracil and oral leucovorin in patients with metastatic colorectal cancer

AU - Shibahara, Kotaro

AU - Yamamoto, Manabu

AU - Kakeji, Yoshihiro

AU - Sakata, Hisanobu

AU - Maehara, Yoshihiko

PY - 2008/5

Y1 - 2008/5

N2 - The aim of this study was to compare the efficacy and toxicity of S-l to an oral combination regimen of tegafur and uracil (UFT) with leucovorin (LV) in metastatic colorectal carcinoma (CRC) patients. Patients and Methods: Fifty-two patients were treated with either S-l (80 mg/m2/d), administered for 28 days every 42 days, or UFT (300 mg/m2/d) and LV (90 mg/d), administered for 28 days every 35 days. The clinical results were compared retrospectively. Results: There were no statistically significant differences in overall response between the two patient groups. The overall response rate was 11.8% in the S-l group, and 11.1% in the UFT/LV group. No statistically significant difference in-time- to progression (TTP) or survival time was observed between the treatments. The median survival time was 29 months with S-l and 12 months with UFT/LV. Conclusion: The oral S-l provided similar safety and efficacy, compared to UFT/LV for metastatic CRC.

AB - The aim of this study was to compare the efficacy and toxicity of S-l to an oral combination regimen of tegafur and uracil (UFT) with leucovorin (LV) in metastatic colorectal carcinoma (CRC) patients. Patients and Methods: Fifty-two patients were treated with either S-l (80 mg/m2/d), administered for 28 days every 42 days, or UFT (300 mg/m2/d) and LV (90 mg/d), administered for 28 days every 35 days. The clinical results were compared retrospectively. Results: There were no statistically significant differences in overall response between the two patient groups. The overall response rate was 11.8% in the S-l group, and 11.1% in the UFT/LV group. No statistically significant difference in-time- to progression (TTP) or survival time was observed between the treatments. The median survival time was 29 months with S-l and 12 months with UFT/LV. Conclusion: The oral S-l provided similar safety and efficacy, compared to UFT/LV for metastatic CRC.

UR - http://www.scopus.com/inward/record.url?scp=45949105002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45949105002&partnerID=8YFLogxK

M3 - Article

C2 - 18630459

AN - SCOPUS:45949105002

SN - 0250-7005

VL - 28

SP - 1779

EP - 1784

JO - Anticancer research

JF - Anticancer research

IS - 3 B

ER -

Retrospective study of S-1 versus tegafur/uracil and oral leucovorin in patients with metastatic colorectal cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this